Institutional members access full text with Ovid®

Share this article on:


Zarranz-Ventura, Javier, MD, PhD, FEBO*,†,‡; Ellabban, Abdallah A., MD*,§; Sim, Dawn A., PhD, FRCOphth; Keane, Pearse A., MD, FRCOphth; Kirkpatrick, James N., MD, FRCOphth*; Sallam, Ahmed A. B., PhD, FRCOphth*,¶

doi: 10.1097/IAE.0000000000001762
Original Study

Purpose: To evaluate the prevalence of foveolar lucency (FL) in surgically closed macular holes by spectral domain optical coherence tomography.

Methods: One hundred forty-two eyes of 132 patients underwent pars plana vitrectomy, internal limiting membrane peeling, and gas tamponade in a 60-month time frame. Anatomical success and FL rates assessed by spectral domain optical coherence tomography, mean preoperative, and postoperative best-measured visual acuity and surgical details were retrospectively analyzed.

Results: Spectral domain optical coherence tomography confirmed closed holes with FL in 33.7% (34/101) of eyes at 1 month, 7.3% (9/123) at 3 months, 4.6% (6/129) at 6 months, and 3% (4/133) at 12 months. Prevalence of FL in closed holes at Month 1 was lower in C3F8-treated eyes (9.5%, 2/21) compared with C2F6 (40.9%, 18/44, P = 0.03) and SF6-treated eyes (38.9%, 14/36, P = 0.05). No differences were observed at Month 3. No differences in best-measured visual acuity change were observed between closed holes with or without FL at Month 1 (−0.14 ± 0.19 vs. −0.11 ± 0.23, P = 0.48) or any of the other time points.

Conclusion: Temporary FL is a highly prevalent feature in successfully closed macular holes. Eyes treated with C3F8 gas had lower rates of FL at Month 1 than C2F6 and SF6-treated eyes. The presence of FL in closed holes does not seem to have any effect on the visual outcomes.

Temporary foveolar lucency is a highly prevalent feature in successfully closed macular holes at Month 1, which seems to be related to the gas tamponade type used and does not affect the final visual outcome.

*Vitreo-Retinal Service, Cheltenham General Hospital, Gloucestershire Hospitals NHS Trust, Cheltenham, United Kingdom;

Vitreo-Retinal Unit, Institut Clínic d´Oftalmologia (ICOF), Hospital Clínic, Barcelona, Spain;

NIHR Biomedical Research Centre for Ophthalmology, Moorfields Eye Hospital NHS Foundation Trust, London, United Kingdom;

§Department of Ophthalmology, Suez Canal University, Ismailia, Egypt; and

Jones Eye Institute, University of Arkansas for Medical Science, Little Rock, Arkansas.

Reprint requests: Javier Zarranz-Ventura, MD, PhD, FEBO, Vitreo-Retinal Service, Cheltenham General Hospital, Sandford Road, Gloucestershire Hospitals NHS Trust, Cheltenham, United Kingdom; e-mail:

None of the authors has any financial/conflicting interests to disclose.

© 2018 by Ophthalmic Communications Society, Inc.